부산대학교 도서관

GLO:HWR/01dec21:ans16878-fig-0001.jpg PHOTO (COLOR): 1 Patent 1's pre-treatment magnetic resonance imaging pre-op showing 5.5 × 4.5 × 7 cm upper rectal lesion. gl GLO:HWR/01dec21:ans16878-fig-0002.jpg PHOTO (COLOR): 2 Patent 1's pre-treatment computed tomography PET pre-op showing avid right gluteal node. gl Long-course chemoradiotherapy with capecitabine was completed and restaging showed a partial response of the primary rectal lesion however the right gluteal node was still prominent. Programmed cell death protein 1 (PD-1) inhibitors such as Pembrolizumab are currently approved by the Food and Drug Administration (FDA) for mismatch repair deficient (dMMR) unresectable colorectal cancer (mCRC). CT abdomen showed a large necrotic transverse colon lesion, extensive omental disease and a 40-mm portocaval node with CT PET confirming avidity resulting in staging of T4N2M1. [Extracted from the article]